Results 191 to 200 of about 614,006 (307)
An enhanced universal gripper combining rigid mechanics with self‐adaptable fingers is presented for industrial automation. The novel six‐bar linkage with integrated compliant pad eliminates mechanical interference while enabling passive shape adaptation.
Muhammad Usman Khalid +7 more
wiley +1 more source
Glycoengineering CAR-T cells to overcome galectin-3-mediated immunosuppression. [PDF]
Lau LS +11 more
europepmc +1 more source
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai +15 more
wiley +1 more source
CAR T cells for pediatric CNS tumors: Clinical experience and reverse translational opportunities. [PDF]
Song KW, Kaur AP, Ramakrishna S.
europepmc +1 more source
Fiber energy harvesters offer unprecedented flexibility and a unique capacity for integration into commercial textiles, overcoming the limitations of bulky and rigid conventional devices. This review summarizes recent advances in fiber‐based energy harvesting and provides strategic outlooks to accelerate technological progress in the field. ABSTRACT As
Hanhwi Jang +8 more
wiley +1 more source
CAR-T cells in solid tumors: engineering, biomarkers, translational pathways and the road ahead. [PDF]
Al Shaer NSH +6 more
europepmc +1 more source
Ovarian Matrisome Dynamics and αvβ3‐Mediated Regulation in Early Follicular Development
The matrisome undergoes dynamic remodeling during early follicular development. Integrin αvβ3 mediates matrisome signals, regulating primordial follicle activation/atresia and secondary follicle growth via Hippo/mTOR pathways, with conserved roles in human ovaries, offering therapeutic targets for ovarian disorders.
Tong Wu +12 more
wiley +1 more source
CAR T cells: the missing piece needed to improve outcomes for children with cancer? [PDF]
Mackall C.
europepmc +1 more source
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun +23 more
wiley +1 more source
CAR-T cells immunotherapy in the treatment of glioblastoma. [PDF]
Królikowska A, Tarnowski M.
europepmc +1 more source

